Evidence map›Paper›PMID 31970527›Full record

ArticleAAPS PharmSciTech2020

Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine After Oral Administration.

Solange A Valdes, Riyad F Alzhrani, Dharmika S P Lansakara-P, Zhengrong Cui

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AAPS PharmSciTech, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Solange A ValdesDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA.
Riyad F AlzhraniDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA.
Dharmika S P Lansakara-PDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA.
Zhengrong CuiDivision of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA. zhengrong.cui@austin.utexas.edu.
The University of Texas at Austin · US

Funding

A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer ChemotherapyR21CA179362 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI CUI, ZHENGRONG · 2015 to 2016
$371k
NCI NIH HHS R21 CA179362
6 · The paper itself

Abstract

Previously, we developed a solid lipid nanoparticle (SLN) formulation of 4-(N)-docosahexaenoyl 2', 2'-difluorodeoxycytidine (DHA-dFdC), a compound with promising antitumor activity. Herein, we studied the feasibility of administering the DHA-dFdC by the oral route using the solid lipid nanoparticles (i.e., DHA-dFdC-SLNs). In simulated gastrointestinal fluids, the DHA-dFdC-SLNs did not aggregate. The release of the DHA-dFdC from the solid lipid nanoparticles in simulated gastrointestinal fluid was slow, but was slightly faster in simulated intestinal fluid than in simulated gastric fluid. In mice orally administered with DHA-dFdC-SLNs, plasma DHA-dFdC concentration vs. time curve has a T

Indexed as

Administration, OralAnimalsBiological AvailabilityDocosahexaenoic AcidsDrug CarriersDrug CompoundingFemaleLipidsMiceMice, Inbred C57BLNanoparticlesPolysorbatesSurvival RateXenograft Model Antitumor AssaysDocosahexaenoic AcidsDrug CarriersLipidsPolysorbatesbioavailabilitymouse survivalnanoparticlesoralpharmacokineticstumor

Identifiers

PMID31970527
PMCPMC8464177
OpenAlexW3003106349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.